Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mulholland, P. J.
Right arrow Articles by Kerr, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulholland, P. J.
Right arrow Articles by Kerr, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:245-248, 2001
© 2001 European Society for Medical Oncology

research-article

Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin

P. J. Mulholland, D. R. Ferry, D. Anderson, S. A. Hussain, A. M. Young, J. E. Cook, E. Hodgkin, L. W. Seymour and D. J. Kerr

1Cancer Research campaign Institute for Cancer Studies, University of Birmingham Queen Elizabeth Hospital. Edgbaston, Birmingham. UK

Cancer Research Campaign Institute for Cancer Studies University of Birmingham Queen Elizabeth Hospital Edgbaston, Birmingham B15 2TH UKD.J.Kerr{at}bham.ac.uk

BACKGROUND:: Quercetin is a naturally occurring flavonoid with many biological activities including inhibition of a number of tyrosine kinases. A phase I, dose-escalation trial of quercetin defined the maximum tolerated dose (MTD) as 1700 mg/m2 three weekly, but the vehicle, dimethyl sulphoxide (DMSO) is unsuitable for further clinical development of quercetin.

PATIENTS AND METHODS:: A water-soluble, pro-drug of quercetin (3'(N-carboxymethyl)carbomyl-3,4',5,7-tetrahydroxyflavone), QC12 has been synthesised. Six cancer patients received 400 mg of QC12 (equivalent to 298 mg of quercetin), orally on day 1 and intravenously (i.v.) in normal saline on day 14.

RESULTS:: Following oral administration of QC12 we were unable to detect QC12 or quercetin in plasma. After i.v. administration, we detected peak plasma concentrations of QC12 of 108.7 ± 41.67 µMolar (µM). A two-compartment model with mean t1/2{alpha} of 0.31 ± 0.27 hours and mean 1/2ß of 0.86 ± 0.78 hours best described the concentration-time curves for QC12. The mean AUC was 44.54 ± 13.0 µM.hour and mean volume of distribution (Vd) of 10.0 ± 6.2 litres (1). Quercetin was found in all patients following i.v. infusion of QC12, with peak levels of quercetin 19.9 ± 11.8 µM. The relative bioavailability of quercetin was estimated to be 20%–25% quercetin released from QC12.

CONCLUSIONS:: QC12 is not orally bioavailable. This water-soluble pro-drug warrants further clinical investigation; starting with a formal phase I, IV, dose-escalation study.

cancer, human, QC12, quercetin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
C. Giuliani, Y. Noguchi, N. Harii, G. Napolitano, D. Tatone, I. Bucci, M. Piantelli, F. Monaco, and L. D. Kohn
The Flavonoid Quercetin Regulates Growth and Gene Expression in Rat FRTL-5 Thyroid Cells
Endocrinology, January 1, 2008; 149(1): 84 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z.-p. Yuan, L.-j. Chen, L.-y. Fan, M.-h. Tang, G.-l. Yang, H.-s. Yang, X.-b. Du, G.-q. Wang, W.-x. Yao, Q.-m. Zhao, et al.
Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
Clin. Cancer Res., May 15, 2006; 12(10): 3193 - 3199.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. W. Graner and D. D. Bigner
Chaperone proteins and brain tumors: Potential targets and possible therapeutics
Neuro-oncol, July 1, 2005; 7(3): 260 - 278.
[Abstract] [PDF]

Home page
 Ann OncolHome page
D. J. Kerr and N. B. La Thangue
Signal transduction blockade and cancer: combination therapy or multi-targeted inhibitors?
Ann. Onc., December 1, 2004; 15(12): 1727 - 1729.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.